These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 11254898)

  • 1. Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice.
    Arnal JF; Castano C; Maupas E; Mugniot A; Darblade B; Gourdy P; Michel JB; Bayard F
    Atherosclerosis; 2001 Apr; 155(2):291-5. PubMed ID: 11254898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats.
    Kostova E; Jovanoska E; Zafirov D; Jakovski K; Maleska V; Slaninka-Miceska M
    Bratisl Lek Listy; 2005; 106(12):407-11. PubMed ID: 16642666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice.
    Jandeleit-Dahm K; Lassila M; Davis BJ; Candido R; Johnston CI; Allen TJ; Burrell LM; Cooper ME
    J Hypertens; 2005 Nov; 23(11):2071-82. PubMed ID: 16208151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin I-converting enzyme-dependent and neutral endopeptidase-dependent generation and degradation of angiotensin II contrarily modulate noradrenaline release: implications for vasopeptidase-inhibitor therapy?
    Raasch W; Dominiak P; Dendorfer A
    J Hypertens; 2005 Aug; 23(8):1597-604. PubMed ID: 16003188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omapatrilat, an angiotensin-converting enzyme and neutral endopeptidase inhibitor, attenuates early atherosclerosis in diabetic and in nondiabetic low-density lipoprotein receptor-deficient mice.
    Levy Z; Dvir A; Shaish A; Trestman S; Cohen H; Levkovietz H; Rhachmani R; Ravid M; Harats D
    Int J Exp Diabesity Res; 2003; 4(1):59-64. PubMed ID: 12745671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat.
    Hegde LG; Yu C; Renner T; Thibodeaux H; Armstrong SR; Park T; Cheruvu M; Olsufka R; Sandvik ER; Lane CE; Budman J; Hill CM; Klein U; Hegde SS
    J Cardiovasc Pharmacol; 2011 Apr; 57(4):495-504. PubMed ID: 21297495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure.
    Xu J; Carretero OA; Liu YH; Yang F; Shesely EG; Oja-Tebbe N; Yang XP
    J Card Fail; 2004 Feb; 10(1):83-9. PubMed ID: 14966779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed.
    Dumoulin MJ; Adam A; Rouleau JL; Lamontagne D
    J Cardiovasc Pharmacol; 2001 Apr; 37(4):359-66. PubMed ID: 11300648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats.
    Pu Q; Touyz RM; Schiffrin EL
    J Hypertens; 2002 May; 20(5):899-907. PubMed ID: 12011651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema.
    Fryer RM; Segreti J; Banfor PN; Widomski DL; Backes BJ; Lin CW; Ballaron SJ; Cox BF; Trevillyan JM; Reinhart GA; von Geldern TW
    Br J Pharmacol; 2008 Mar; 153(5):947-55. PubMed ID: 18084312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat.
    Dalzell JR; Seed A; Berry C; Whelan CJ; Petrie MC; Padmanabhan N; Clarke A; Biggerstaff F; Hillier C; McMurray JJ
    Cardiovasc Ther; 2014 Feb; 32(1):13-8. PubMed ID: 24138103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasopeptidase inhibition: a new concept in blood pressure management.
    Burnett JC
    J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men.
    Regamey F; Maillard M; Nussberger J; Brunner HR; Burnier M
    Hypertension; 2002 Sep; 40(3):266-72. PubMed ID: 12215465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelial permeability in vitro and in vivo: protective actions of ANP and omapatrilat in experimental atherosclerosis.
    Ichiki T; Izumi R; Cataliotti A; Larsen AM; Sandberg SM; Burnett JC
    Peptides; 2013 Oct; 48():21-6. PubMed ID: 23927843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omapatrilat decreased macrophage oxidative status and atherosclerosis progression in atherosclerotic apolipoprotein E-deficient mice.
    Hayek T; Hamoud S; Keidar S; Pavlotzky E; Coleman R; Aviram M; Kaplan M
    J Cardiovasc Pharmacol; 2004 Jan; 43(1):140-7. PubMed ID: 14668580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of atherosclerotic changes in cholesterol-fed rabbits treated with an oral inhibitor of neutral endopeptidase 24.11 (EC 3.4.24.11).
    Kugiyama K; Sugiyama S; Matsumura T; Ohta Y; Doi H; Yasue H
    Arterioscler Thromb Vasc Biol; 1996 Aug; 16(8):1080-7. PubMed ID: 8696950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasopeptidase inhibitors, neutral endopeptidase inhibitors, and dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
    Nawarskas J; Rajan V; Frishman WH
    Heart Dis; 2001; 3(6):378-85. PubMed ID: 11975822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of omapatrilat in low, normal, and high renin experimental hypertension.
    Trippodo NC; Robl JA; Asaad MM; Fox M; Panchal BC; Schaeffer TR
    Am J Hypertens; 1998 Mar; 11(3 Pt 1):363-72. PubMed ID: 9544878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.
    Blais C; Fortin D; Rouleau JL; Molinaro G; Adam A
    J Pharmacol Exp Ther; 2000 Nov; 295(2):621-6. PubMed ID: 11046097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406.
    Sulpizio AC; Pullen MA; Edwards RM; Louttit JB; West R; Brooks DP
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1306-13. PubMed ID: 16144980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.